Peroxisome proliferator-activated receptor-&gamma; agonists and diabetes: Current evidence and future perspectives | Zendy

D. Di Marzio | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Peroxisome proliferator-activated receptor-γ agonists and diabetes: Current evidence and future perspectives

Author(s) -

D. Di Marzio

Publication year - 2008

Publication title -

vascular health and risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.892

H-Index - 68

eISSN - 1178-2048

pISSN - 1176-6344

DOI - 10.2147/vhrm.s993

Subject(s) - medicine , diabetes mellitus , peroxisome proliferator activated receptor , type 2 diabetes , receptor , ppar agonist , endocrinology , pharmacology , bioinformatics , biology

Since their initial availability in 1997, the thiazolidinediones (TZDs) have become one of the most commonly prescribed classes of medications for type 2 diabetes. In addition to glucose control, the TZDs have a number of pleiotropic effects on myriad traditional and non-traditional risk factors for diabetes. TZDs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function and fibrinolytic state. In this review, we summarise the experimental, preclinical and clinical data regarding the effects of the TZDs in conditions for which they are indicated and discuss their potential in the treatment of other conditions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research